Training Program in Pharmacology

药理学培训计划

• 批准号: 10656570
• 负责人: Donald M Bers
• 金额: $ 41.43万
• 依托单位: UNIVERSITY OF CALIFORNIA AT DAVIS
• 依托单位国家: 美国
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-07-01 至 2027-06-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10656570
• 关键词: Pharmacology; Training Programs

TRAINING PROGRAM IN PHARMACOLOGY ABSTRACT: The overarching goal of this predoctoral Training Program in Pharmacology (TPPh) is to educate next generation of biomedical researchers in the concepts of drug discovery and development, inclusive a clinical perspective. The four focus areas of this TPPh are cardiovascular, neurological, and immunological diseases and cancer. UC Davis is a world leader in drug development with multiple trainers bringing drugs to the clinic (most recently Dr. Rogawski the novel post-partum antidepressant Brexanolone) and biologics including gene therapy vectors with >20 ongoing clinical trials (Director Dr. Nolta). Trainees from Pharmacology & Toxicology, Physiology, Biomedical Engineering and Neuroscience develop expertise in diverse areas. Areas include classic pharmacology & drug target identification with cutting edge methods in biochemistry, structural biology, genomics & proteomics, molecular and cell biology; structural modeling and rational drug design; medicinal chemistry; high & superresolution imaging; electrophysiology; behavioral physiology; engineering of microfluidic and other devices; animal models of disease; novel in vivo whole animal imaging; and translational therapeutics in clinical trials including stem cell and genetic therapies. The TPPh will provide focused and student-tailored small group training in the core principles of pharmacology for non-pharmacology trainees, and enmesh these students with pharmacology students for interdisciplinary group learning in drug development. A related goal is to enable all trainees to communicate and collaborate across the large array of research disciplines they represent. This goal is mainly realized in a highly innovative student-driven, project-oriented course Problem Solving in Pharmacological Sciences, which rejuvenates itself every year based on student initiative and interest. In this way our TPPh produces experts with a variety of backgrounds that can effectively communicate and collaborate with experts from other related disciplines in the increasingly complex realm of drug development. UC Davis grants more bachelors and doctoral degrees in biological sciences than any other U.S. university. It received $961 million in extramural research funding in 2020/21, which places it, as in earlier years, among the top 10 public universities. The 30 training faculty are from 14 departments in 6 colleges, where extensive collaborative interactions already exist. Trainers provide in depth expertise that ranges from identifying novel therapeutic molecular targets and development of therapeutic molecules to clinical drug and stem cell trials at the NIH-funded UC Davis Clinical and Translational Science Center (CTSC) and NIH-designated Cancer Center. Powerful and numerous state- of-the-art core facilities and centers will provide trainees with outstanding research opportunities spanning from Chemistry’s emphasis on pharmaceutical chemistry to unique animal models (internationally recognized mouse biology center, Agricultural & Veterinary Schools, Primate Center).

药理学培训计划 抽象的： 药理学博士前培训计划 (TPPh) 的总体目标是教育下一代 一代生物医学研究人员在药物发现和开发的概念中，包括 该 TPPh 的四个重点领域是心血管、神经和免疫学。 加州大学戴维斯分校是药物开发领域的世界领先者，拥有多名培训师带来药物。 到诊所（最近是 Rogawski 博士的新型产后抗抑郁药 Brexanolone）和生物制剂 包括正在进行超过 20 项临床试验的基因治疗载体（来自主任实习生 Dr. Nolta）。 药理学和毒理学、生理学、生物医学工程和神经科学发展专业知识 不同领域包括经典药理学和药物靶点识别以及尖端方法。 生物化学、结构生物学、基因组学和蛋白质组学、分子和细胞结构建模和 药物化学设计；高分辨率和超分辨率成像； 生理学；微流体和其他疾病动物模型的工程； 动物成像；以及临床试验中的转化疗法，包括干细胞和基因疗法。 TPPh 将提供针对药理学核心原理的有针对性的、为学生量身定制的小组培训 针对非药理学实习生，并将这些学生与药理学学生结合起来进行跨学科研究 药物开发中的小组学习的一个相关目标是使所有学员能够进行沟通和协作。 他们所代表的众多研究学科主要是通过高度创新来实现的。 以学生为主导、以项目为导向的课程“药理学科学问题解决”，使学生焕发活力 每年都会根据学生的主动性和兴趣，通过这种方式，我们的 TPPh 培养出各种各样的专家。 能够与其他相关学科的专家进行有效沟通和协作的背景 在日益复杂的药物开发领域，加州大学戴维斯分校授予更多学士和博士学位。 它获得的生物科学学位数量超过任何其他美国大学，获得了 9.61 亿美元的校外研究资金。 2020/21 学年的资金投入，与往年一样，它跻身前 10 名公立大学 30 所培训院校之列。 教师来自 6 个学院的 14 个系，这些学院已经存在广泛的协作互动。 培训师提供深入的专业知识，范围从识别新的治疗分子靶点到 在 NIH 资助的加州大学戴维斯分校临床中心开发用于临床药物和干细胞试验的治疗分子 和转化科学中心 (CTSC) 以及 NIH 指定的癌症中心。 最先进的核心设施和中心将为学员提供跨领域的杰出研究机会 从化学对药物化学的重视到独特的动物模型（国际公认的 小鼠生物学中心、农业和兽医学校、灵长类动物中心）。